ProCE Banner Series

Hit the Ground Running in Crohn’s Disease: A Managed Care Guide to Advanced Biologic Therapies and Early Interventions to Improve Long-term Outcomes

Interleukin (IL)-23 inhibitors have emerged as effective biologic therapies for Crohn’s disease (CD), associated with rapid symptom improvement and durable remission. Because patients with moderate to severe CD experience the best outcomes when they receive early intervention with the most effective therapies, this program has been developed to improve the abilities of managed care professionals in applying evidence on IL-23 antagonists to optimize care for patients with CD. 

  ACPE-P
Who Should Attend

The target audience for this activity is population healthcare decision-makers involved in the care of patients with Crohn’s disease, comprising managed care pharmacists, payers, pharmacy benefit managers, and key managed care pharmacy stakeholders, pharmacy directors, chief pharmacy officers, and other managed care professionals, as well as members of integrated delivery systems, such as specialty pharmacists.

All Events

Hit the Ground Running in Crohn’s Disease: A Managed Care Guide to Advanced Biologic Therapies and Early Interventions to Improve Long-term Outcomes

Upcoming Events

April

01

2025

11:30 AM - 1:30 PM Central Time (CT)

In-person

George E. Brown Convention Center, 1001 Avenida De Las Americas, Houston, Texas 77010

12:00 PM - 1:30 PM Central Time (CT)

Virtual

April

21

2025

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve knowledge and competence of learners regarding their understanding of the latest efficacy and safety data for selective IL-23 inhibitors for Crohn’s disease and the application of these data to managed care decision-making to facilitate prompt treatment initiation and improve patient outcomes.

Target Audience
The target audience for this activity is population healthcare decision-makers involved in the care of patients with Crohn’s disease, comprising managed care pharmacists, payers, pharmacy benefit managers, and key managed care pharmacy stakeholders, pharmacy directors, chief pharmacy officers, and other managed care professionals, as well as members of integrated delivery systems, such as specialty pharmacists.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Analyze the safety and efficacy data informing the use of selective IL-23 inhibitors in moderate to severe CD

  • Assess the contribution of suboptimal therapy to healthcare utilization and costs for patients with moderate to severe CD

  • Identify managed care considerations that incorporate evidence-based data on novel biologic therapies into formulary decisions and pathway development to prevent delays in therapy and improve clinical outcomes in the management of moderate to severe CD

Accreditation

CE Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number (specific to each event) has been assigned to this live application-based activity (initial release date 4/1/2025). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by ProCE, LLC

Supported by an educational grant from Lilly.

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191